Considering the differential expression pattern of HER2 and Ki-67 mentioned above, it is reasonable to imply that the expression level of SSR3 may also contribute to the distinction of luminal breast cancer from other breast cancer subtypes. The gene discussed is SSR3; the disease is breast cancer.